TY - JOUR
T1 - COVID-19
T2 - Staging of a New Disease
AU - Cordon-Cardo, Carlos
AU - Pujadas, Elisabet
AU - Wajnberg, Ania
AU - Sebra, Robert
AU - Patel, Gopi
AU - Firpo-Betancourt, Adolfo
AU - Fowkes, Mary
AU - Sordillo, Emilia
AU - Paniz-Mondolfi, Alberto
AU - Gregory, Jill
AU - Krammer, Florian
AU - Simon, Viviana
AU - Isola, Luis
AU - Soon-Shiong, Patrick
AU - Aberg, Judith A.
AU - Fuster, Valentin
AU - Reich, David L.
N1 - Funding Information:
We would like to acknowledge the generous support of the JPB Foundation, the Steven & Alexandra Cohen Foundation, and the Open Philanthropy Project (#2020-215611) as well as other philanthropic donations. CCC, AW, A.F.-B. F.K. and V.S. are recipients of a grant/contract from NCI; this effort was deliberated with Leidos Biomedical Research Inc./NCI over the last several months and is now going to be supported by the Serological Sciences Network (SeroNet). This project will be funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. We would like to thank Bethany Percha for help with epidemiologic estimates of SARS-CoV-2-positive patients within the Mount Sinai Health System.We would like to thank Patricia Spilman and Phil Yang for their helpful edits. C.C.-C. A.F.-B. F.K. and V.S. as part of Mount Sinai, report that the institution has licensed SARS-CoV-2 serological assays to commercial entities and have filed for patent protection for serological assays. R.S. reports to be associated with SEMA4. P.S.-S. is the chief executive officer and majority shareholder of both ImmunityBio, Inc. and NantKwest, Inc. and is developing a qLAMP assay.
Funding Information:
We would like to acknowledge the generous support of the JPB Foundation , the Steven & Alexandra Cohen Foundation , and the Open Philanthropy Project ( #2020-215611 ) as well as other philanthropic donations. CCC, AW, A.F.-B., F.K., and V.S. are recipients of a grant/contract from NCI; this effort was deliberated with Leidos Biomedical Research Inc./NCI over the last several months and is now going to be supported by the Serological Sciences Network (SeroNet). This project will be funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. We would like to thank Bethany Percha for help with epidemiologic estimates of SARS-CoV-2-positive patients within the Mount Sinai Health System.We would like to thank Patricia Spilman and Phil Yang for their helpful edits.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11/9
Y1 - 2020/11/9
N2 - Coronavirus disease 2019 (COVID-19), like cancer, is a complex disease with clinical phases of progression. Initially conceptualized as a respiratory disease, COVID-19 is increasingly recognized as a multi-organ and heterogeneous illness. Disease staging is a method for measuring the progression and severity of an illness using objective clinical and molecular criteria. Integral to cancer staging is “metastasis,” defined as the spread of a disease-producing agent, including neoplastic cells and pathogens such as certain viruses, from the primary site to distinct anatomic locations. Staging provides valuable frameworks and benchmarks for clinical decision-making in patient management, improved prognostication, and evidence-based treatment selection.
AB - Coronavirus disease 2019 (COVID-19), like cancer, is a complex disease with clinical phases of progression. Initially conceptualized as a respiratory disease, COVID-19 is increasingly recognized as a multi-organ and heterogeneous illness. Disease staging is a method for measuring the progression and severity of an illness using objective clinical and molecular criteria. Integral to cancer staging is “metastasis,” defined as the spread of a disease-producing agent, including neoplastic cells and pathogens such as certain viruses, from the primary site to distinct anatomic locations. Staging provides valuable frameworks and benchmarks for clinical decision-making in patient management, improved prognostication, and evidence-based treatment selection.
UR - http://www.scopus.com/inward/record.url?scp=85093943936&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2020.10.006
DO - 10.1016/j.ccell.2020.10.006
M3 - Comment/debate
C2 - 33086031
AN - SCOPUS:85093943936
SN - 1535-6108
VL - 38
SP - 594
EP - 597
JO - Cancer Cell
JF - Cancer Cell
IS - 5
ER -